Publication | Closed Access
The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis.
177
Citations
0
References
1968
Year
ImmunohematologyImmunologyBlood CellImmunotherapyThrombosisC′1a InhibitorLaboratory HematologyHematologyImmunochemistryClinical ChemistryLaboratory MedicineHuman SerumHealth SciencesAllergyAutoimmune DiseaseVascular PharmacologyAutoimmunitySerum InhibitionHeme HomeostasisPharmacologyComplement SystemStoichiometric MeasurementHemostasisPathogen ClearanceMedicineImmune Hemolysis
The assay measures the α‑2‑globulin inhibitor’s stoichiometric blockade of C1a in immune hemolysis, defining a hemolytic unit that inhibits 63 % of C1a and allowing activity to be quantified in serum after C1 precipitation. The inhibitor blocks C1a equally in fluid phase and on cells, with normal serum activity averaging 37,445 ± 17,790 units/ml, while hereditary angioedema patients exhibit a 99 % reduction.
Summary A sensitive technique for the measurement of the activity of the α-2-globulin inhibitor of the activated first component of complement has been described. The reaction is based on the ability of this inhibitor to block C′1a in a stoichiometric fashion in immune hemolysis. A hemolytic unit of C′1aINH has been defined as the amount required to inhibit 63% of one effective molecule of C′1a in the presence of a total dose of from 1.5 to 2.5 effective molecules per cell. The C′1a inhibitor is stoichiometrically depleted by its interaction with fluid phase hemolytically active C′1a. C′1aINH is equally effective in blocking C′1a in the fluid phase or on the cell. C′1aINH activity can be measured in human serum after removal of C′1 by precipitating the latter at low ionic strength, pH 7.5. Normal levels for C′1aINH activity are 37,445 ± 17,790 units/ml. Patients with hereditary angioedema were found to have a 99% reduction in C′1aINH activity.